009420 — Hanall Biopharma Co Cashflow Statement
0.000.00%
Last trade - 00:00
- KR₩2tn
- KR₩2tn
- KR₩135bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 19,174 | 19,764 | 8,896 | 251 | 3,509 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 2,585 | -8,496 | 4,929 | 6,425 | 2,877 |
Unusual Items | |||||
Purchased R&D | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -3,983 | -13,233 | -15,710 | 15,475 | 20,010 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Net Change in Other Assets & Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 20,491 | 929 | 840 | 25,204 | 29,643 |
Capital Expenditures | -8,276 | -7,390 | -9,002 | -7,677 | -9,198 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -28,321 | 5,072 | 17,032 | -2,915 | -2,690 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -36,597 | -2,318 | 8,030 | -10,592 | -11,887 |
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -460 | -519 | -307 | -10,644 | -814 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -16,562 | -1,920 | 8,594 | 4,047 | 16,882 |